Retatrutide and heartburn is a question arising as this investigational triple incretin receptor agonist advances through clinical trials. Retatrutide acts on GLP-1, GIP, and glucagon receptors simultaneously, producing notable effects on gastric motility that may predispose some individuals to acid reflux and heartburn-type symptoms. Although retatrutide is not yet licensed by the MHRA or EMA, phase 2 trial data indicate that gastrointestinal side effects are among the most commonly reported adverse events. This article examines the available evidence, practical management strategies, and when to seek medical advice.

Retatrutide and Heartburn: What the Evidence Shows

Retatrutide's GLP-1 receptor activity slows gastric emptying, providing a plausible biological basis for heartburn; phase 2 trial data confirm gastrointestinal side effects are common, though heartburn was not consistently itemised as a standalone adverse event.

Retatrutide is an investigational triple incretin receptor agonist administered as a weekly subcutaneous injection in clinical trials, with dose escalation used to improve tolerability.^[1][2] Phase 3 programmes are currently underway following promising phase 2 results. It acts simultaneously on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, producing significant reductions in body weight and improvements in glycaemic control. As of the time of writing, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), meaning it is not yet an approved medicine in the UK. No UK Summary of Product Characteristics (SmPC) exists; the available evidence comes from clinical trial data rather than regulatory product information.

Heartburn — medically referred to as gastro-oesophageal reflux — occurs when stomach acid travels back up into the oesophagus, causing a burning sensation in the chest or throat. Because no licensed SmPC exists for retatrutide, there is no formally confirmed list of adverse effects; however, the drug's mechanism of action provides a plausible biological basis for gastrointestinal discomfort. GLP-1 receptor agonism is well established to slow gastric emptying, which can increase intra-gastric pressure and potentially promote acid reflux in susceptible individuals.^[4][10]

Data from a phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated that gastrointestinal side effects were among the most commonly reported adverse events with retatrutide, particularly at higher doses. Whilst heartburn or reflux were not consistently itemised as standalone symptoms in trial reporting, nausea, vomiting, and upper abdominal discomfort — symptoms that frequently co-exist with reflux — were consistently noted. Patients and clinicians should therefore be aware that heartburn-type symptoms may plausibly occur, even if the evidence base continues to evolve as phase 3 data become available.

Reported Gastrointestinal Side Effects in Clinical Trials

Phase 2 trial data show nausea, vomiting, diarrhoea, constipation, and upper abdominal pain are the most frequently reported gastrointestinal side effects, with incidence increasing at higher doses and most events being mild to moderate.

The gastrointestinal side-effect profile of retatrutide observed in phase 2 trials is broadly consistent with other GLP-1-based therapies, such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro), though retatrutide's additional glucagon receptor activity means its full profile may differ in ways that phase 3 data will clarify. In the phase 2 dose-escalation study (Jastreboff et al., NEJM, 2023), gastrointestinal adverse events were reported in a substantial proportion of participants, with incidence increasing at higher doses. The most frequently reported symptoms included:

• Nausea (the most common, with rates varying by dose — readers should refer to the published trial data and supplementary tables for dose-specific figures)

• Vomiting

• Diarrhoea

• Constipation

• Upper abdominal pain or discomfort

• Decreased appetite

These effects are largely attributable to the drug's action on GLP-1 receptors in the gastrointestinal tract, which slow gastric motility and alter gut hormone signalling. Slowed gastric emptying means food and acid remain in the stomach for longer, which can predispose individuals to symptoms that overlap with heartburn and reflux, including a sensation of fullness, regurgitation, and burning discomfort.

Most gastrointestinal side effects observed in trials were described as mild to moderate in severity and tended to be transient, often improving as the body adjusted to the medication during dose escalation.^[1] Serious gastrointestinal events were not prominently reported in the available phase 2 data, though the limited duration and sample size of phase 2 studies mean that longer-term phase 3 data will provide a more complete safety picture.

It is also worth noting that rapid weight loss associated with GLP-1 receptor agonist therapy is linked to an increased risk of gallstone formation and gallbladder disease (cholecystitis), a class effect recognised in the SmPCs for semaglutide and tirzepatide.^[10][11] This risk is relevant to retatrutide given its significant weight-loss effect, and patients should be aware of related symptoms (see 'When to Seek Medical Advice' below).

Patients should not interpret the absence of a specific heartburn label in trial data as confirmation that the symptom cannot occur — individual responses to any medicine can vary considerably, and this investigational profile may be updated as further evidence emerges.

Managing Heartburn and Reflux Whilst Taking Retatrutide

NHS and NICE-aligned strategies — including smaller meals, avoiding trigger foods, remaining upright after eating, and using alginate preparations or short-term PPIs — can help manage heartburn symptoms; dose titration should only be adjusted under prescriber guidance.

If you experience heartburn or reflux-type symptoms whilst taking retatrutide (or any GLP-1-based therapy), there are several practical strategies that may help reduce discomfort. These align with NHS and NICE guidance on the management of gastro-oesophageal reflux disease (GORD) and are appropriate as initial self-care measures.

Dietary and lifestyle adjustments:

• Eat smaller, more frequent meals rather than large portions, which can exacerbate delayed gastric emptying

• Avoid foods and drinks known to trigger reflux, including fatty or spicy foods, caffeine, alcohol, and carbonated beverages

• Remain upright for at least two to three hours after eating; avoid lying down immediately after meals

• Elevate the head of your bed by approximately 15–20 cm if night-time symptoms are troublesome

• Avoid eating within two to three hours of bedtime

• If you smoke, stopping smoking can significantly reduce reflux symptoms and is strongly recommended

• Maintaining a healthy weight supports overall digestive health, though weight loss with retatrutide should be gradual and medically supervised

Medication considerations: For typical reflux symptoms, alginate-based preparations (such as Gaviscon Advance) are recommended as an effective first-line option in UK practice, as they form a physical barrier over stomach contents and can provide prompt symptomatic relief.^[8][9] Standard antacids (such as calcium carbonate preparations) may also offer short-term relief. These are generally considered safe to use alongside retatrutide, though you should confirm this with your prescriber or pharmacist.

If symptoms are persistent or moderate in severity, a short course (typically two to four weeks) of a proton pump inhibitor (PPI) such as omeprazole — available over the counter in the UK — may be considered, ideally following discussion with a pharmacist or GP.^[8][9] OTC PPI use should be short-term; if symptoms persist or recur after this period, seek GP review rather than continuing to self-treat.

It is also worth reviewing whether your retatrutide dose has recently been increased, as gastrointestinal symptoms are more common during dose escalation. In some cases, slowing the titration schedule under medical supervision can meaningfully reduce side-effect burden without compromising therapeutic benefit. Do not adjust your dose independently without guidance from your prescriber.

References: NHS — Acid reflux and GORD; NICE CKS — Dyspepsia: gastro-oesophageal reflux disease; BNF — antacids, alginates, and proton pump inhibitors.

When to Seek Medical Advice About Digestive Symptoms

Seek urgent medical attention for chest pain, vomiting blood, severe abdominal pain, or black stools; contact your GP if reflux persists beyond three weeks, dysphagia occurs, or NICE NG12 red-flag features are present.

Whilst mild heartburn and gastrointestinal discomfort may be manageable with self-care, certain symptoms warrant prompt medical attention. It is important to distinguish between common, transient side effects and signs that could indicate a more serious underlying condition.

Contact your GP if reflux or heartburn symptoms persist for three weeks or more, even if they seem mild, or sooner if symptoms are severe or accompanied by any of the features below.

Seek urgent medical advice or call 999 if you experience:

• Chest pain accompanied by breathlessness, sweating, or pain spreading to your arm or jaw — these may indicate a cardiac cause and require immediate assessment

• Vomiting blood or passing black, tarry stools, which may indicate gastrointestinal bleeding

• Severe or sudden abdominal pain, particularly in the upper abdomen or radiating to the back — this could suggest pancreatitis, a rare but recognised risk with GLP-1 receptor agonists (as noted in the SmPCs for semaglutide and tirzepatide)

Contact your GP promptly if you experience:

• Difficulty swallowing (dysphagia) or pain on swallowing (odynophagia) — these are red-flag symptoms that require assessment regardless of age

• Unexplained weight loss beyond what is expected from the medication

• Persistent nausea or vomiting that is not improving

• Signs of dehydration following repeated vomiting, including dizziness, reduced urination, or extreme thirst

• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice) — these may suggest gallbladder disease, a recognised risk with rapid weight loss and GLP-1 receptor agonist therapy

NICE NG12 urgent referral criteria: If you are aged 55 or over and have unexplained weight loss alongside upper abdominal pain, reflux, or dyspepsia, your GP should consider an urgent suspected cancer referral. Dysphagia at any age also warrants urgent assessment under NICE NG12 criteria.

Pancreatitis is a serious adverse event associated with the GLP-1 receptor agonist class. Although the absolute risk is low, UK prescribing guidance for similar agents recommends that patients are counselled about this risk and advised to seek immediate medical attention if they develop sudden, severe abdominal pain. Retatrutide's triple-receptor mechanism means its full safety profile is still being characterised through ongoing clinical trials, and vigilance is particularly important during this period.

Never dismiss persistent digestive symptoms as simply a side effect without professional evaluation, especially if they are new, severe, or accompanied by other concerning features.

References: NHS — Acid reflux and GORD (when to seek help); NICE NG12 — Suspected cancer: recognition and referral; eMC SmPCs for semaglutide and tirzepatide (class warnings).

Talking to Your GP or Prescriber About Side Effects

All gastrointestinal side effects should be reported to your trial team or GP; suspected adverse reactions to retatrutide can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Open communication with your GP or prescriber is essential when taking any investigational medicine. Because retatrutide is not yet licensed in the UK, individuals accessing it would typically be doing so through a regulated clinical trial. It is strongly advisable not to obtain retatrutide or any unlicensed medicine from unregulated or overseas websites, as this carries significant risks to your safety and means you will not have appropriate medical oversight. The MHRA provides guidance on buying medicines safely online (available at gov.uk/guidance/buying-medicines-online). If you are unsure about the source of any medicine you have been offered, speak to your NHS GP or pharmacist.

If you are participating in a clinical trial, all side effects — including gastrointestinal symptoms such as heartburn — should be reported to the trial team as part of the pharmacovigilance process. This contributes to the broader evidence base for the medicine's safety profile and is an important part of how medicines are evaluated before licensing.

When discussing gastrointestinal side effects, including heartburn, with your prescriber, it is helpful to:

• Keep a symptom diary noting when symptoms occur, their severity, duration, and any potential triggers

• Report all concurrent medications and supplements, as some — including non-steroidal anti-inflammatory drugs (NSAIDs) and certain antibiotics — can independently worsen reflux or interact with gastrointestinal function^[8][9]

• Ask about dose titration options if symptoms are significantly affecting your quality of life

• Discuss whether a formal GORD assessment is warranted, particularly if symptoms are persistent — your GP may consider Helicobacter pylori testing or referral for endoscopy based on NICE CKS and NG12 criteria

Your prescriber may refer you to a gastroenterologist if symptoms are complex or do not resolve with standard management.

If you experience any suspected adverse reaction to retatrutide, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This applies to unlicensed medicines as well as licensed ones, and your report helps build the UK's understanding of emerging medicines and their real-world safety.

Your health and safety remain the priority, and no side effect — however seemingly minor — should go undiscussed with a qualified healthcare professional.

References: MHRA Yellow Card scheme (yellowcard.mhra.gov.uk); MHRA guidance on buying medicines online; NICE CKS — Dyspepsia: gastro-oesophageal reflux disease; NICE NG12 — Suspected cancer: recognition and referral.

Frequently Asked Questions